0001079973-24-000604.txt : 20240429 0001079973-24-000604.hdr.sgml : 20240429 20240429081010 ACCESSION NUMBER: 0001079973-24-000604 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scorpius Holdings, Inc. CENTRAL INDEX KEY: 0001476963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262844103 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35994 FILM NUMBER: 24886689 BUSINESS ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 400 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-240-7133 MAIL ADDRESS: STREET 1: 627 DAVIS DRIVE STREET 2: SUITE 400 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: NightHawk Biosciences, Inc. DATE OF NAME CHANGE: 20220502 FORMER COMPANY: FORMER CONFORMED NAME: HEAT BIOLOGICS, INC. DATE OF NAME CHANGE: 20091117 8-K 1 scpx_8k.htm FORM 8-K
false 0001476963 0001476963 2024-04-29 2024-04-29 0001476963 us-gaap:CommonStockMember 2024-04-29 2024-04-29 0001476963 SCPX:CommonStockPurchaseRightsMember 2024-04-29 2024-04-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): April 29, 2024

 

Scorpius Holdings, Inc.

(Exact name of registrant as specified in charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-35994 26-2844103
(Commission File Number) (IRS Employer Identification No.)

 

627 Davis Drive, Suite 400

Morrisville, North Carolina 27560

(Address of principal executive offices and zip code)

 

(919) 240-7133

(Registrant’s telephone number including area code)

 

 

(Former Name and Former Address)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0002 par value per share SCPX NYSE American LLC
Common Stock Purchase Rights None NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

 

Item 2.02 Results of Operations and Financial Condition.

On April 29, 2024, Scorpius Holdings, Inc., a Delaware corporation (the “Registrant”), issued the attached press release that included financial information for its fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit Number   Description
99.1   Press release dated April 29, 2024
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
     

  

  

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  April 29, 2024

SCORPIUS HOLDINGS, INC.

   
     
  By: /s/ Jeffrey Wolf
  Name:

Jeffrey Wolf

  Title:

Chairman, President and

Chief Executive Officer

 

 

 

 EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023

Durham, NC – April 29, 2024 –Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2023.

Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are executing our plan to augment sales and drive revenue, as evidenced by the $4.8 million of revenue from continuing operations that we reported in the fourth quarter of 2023. This represents a 570% increase from the third quarter of 2023, and a 226% increase compared to revenue for the first nine months of the year. To date, Scorpius’s successful business development efforts have resulted in the recording of more than $20 million of contract bookings. We believe our bookings, coupled with the strong interest in our microbial and mammalian capabilities and promising pipeline of new opportunities, positions us well for significant growth in 2024 and beyond.”

"As the large molecule drug substance CDMO market is projected to grow from $10 billion in 2023 to $21 billion by 20301, there is a substantial need for enhanced industry capacity. With our scalable business model and the rising demand for our large molecule CDMO services, we believe that we are well-positioned to capture a meaningful share of this market. Moreover, we expect Scorpius’ growth to accelerate in 2024 and remain optimistic about becoming cash flow positive by early 2025. With the completion of our facility and divestiture of our research and non-core assets, we substantially reduced our operating expenses in the fourth quarter of 2023. As a result, we believe the future for Scorpius could not be brighter as our 60,000+ sq. ft. campus provides us sufficient capacity to grow our business with minimal additional capex requirements, which we believe is the key to maximizing profits and returns for our shareholders,” concluded Mr. Wolf.

2023 Financial Results

• For the year ended December 31, 2023, the Company recognized $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royalty revenue from continuing operations. For the year ended December 31, 2022, revenue consisted of $0.1 million of contract revenue and $0.3 million of CPRIT grant revenue from continuing operations. The revenue does not reflect any revenue derived from Elusys Therapeutics which was divested in December 2023 and reported in discontinued operations. The increase in contract revenue is primarily due to the execution of process development contracts, a substantial portion of which was from one customer, from which we no longer anticipate deriving significant revenue.

 
 

 • For the year ended December 31, 2023, the Company recognized $2.7 million of cost of revenues from product sales as compared to $0.1 million for the year ended December 31, 2022. The increase of $2.6 million was due to the cost of executing on process development contracts.

• Selling, general and administrative expenses for the years ended December 31, 2023, and 2022 were $26.2 million and $20.1 million, respectively. The increase of $6.1 million was primarily due to increased sales and marketing costs for marketing the Company to the CDMO market space of $2.4 million, an increase in labor for Scorpius to support operations of $1.8 million, an increase in legal, accounting, and other professional expenses to manage the business of $1.8 million, an increase in facilities expenses from the opening of our San Antonio facility of $1.4 million, an increase in depreciation and amortization of $0.8 million due to increased investment in equipment and the amortization of right to use assets, offset by decreases in stock-based compensation of $1.1 million, a decrease in other facility and operation expenses of $0.4 million, a reduced need for outside consultants associated with the build-out of Scorpius of $0.4 million, and a reduction of insurance costs of $0.1 million.

• In-process research and development (“IPR&D”) impairment was $0 and $3.5 million for the years ended December 31, 2023, and 2022, respectively. IPR&D was fully impaired during the third quarter of 2022 as the PTX-35 trial did not progress to Phase 2.

• Net loss attributable to Scorpius was approximately $45.2 million, or ($1.74) per basic and diluted share, for the year ended December 31, 2023, compared to approximately $43.4 million, or ($1.70) per basic and diluted share, for the year ended December 31, 2022.

• As of December 31, 2023, the Company had approximately $2.4 million in cash, cash equivalents, and short-term investments.

Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), Scorpius reports that its audited financial statements for the year ended December 31, 2023 and 2022, included in its 2023 annual report on Form 10-K, contain an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to the Company’s ability to continue as a going concern due to the fact that the Company has suffered recurring losses from operations and has not generated significant revenue or positive cash flows from operations.

_________________________

1 SkyQuest Large Molecule Industry Forecast, February 2024

 
 

Scorpius Holdings, Inc.

Scorpius Holdings Inc. is an integrated CDMO focused on manufacturing biologic and cell therapy programs for our clients. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.

 

Forward-Looking Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as

the bookings, coupled with the strong interest in the Company’s microbial and mammalian capabilities and promising pipeline of new opportunities, positions it well for significant growth in 2024 and beyond; the large molecule drug substance CDMO market projected growth from $10 billion in 2023 to $21 billion by 2030; being well-positioned to capture a meaningful share of the market; Scorpius’ growth accelerating in 2024 and becoming cash flow positive by early 2025; the future for Scorpius could not be brighter as its 60,000+ sq. ft. campus provides it sufficient capacity to grow its business with minimal additional capex requirements, and maximizing profits and returns for its shareholders. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its bookings and continue to grow revenue; the ability to capture a meaningful market share; he ability to become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

 

Media and Investor Relations Contact

David Waldman

+1 919 289 4017

ir@scorpiusbiologics.com

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 scpx-20240429.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 scpx-20240429_def.xml XBRL DEFINITION FILE EX-101.LAB 6 scpx-20240429_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Rights [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Common Stock No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 scpx-20240429_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 29, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 29, 2024
Entity File Number 001-35994
Entity Registrant Name Scorpius Holdings, Inc.
Entity Central Index Key 0001476963
Entity Tax Identification Number 26-2844103
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 627 Davis Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code (919)
Local Phone Number 240-7133
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Common Stock Common Stock, $0.0002 par value per share
Trading Symbol SCPX
Security Exchange Name NYSEAMER
Common Stock Purchase Rights [Member]  
Common Stock Common Stock Purchase Rights
Trading Symbol None
Security Exchange Name NYSEAMER
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://scorpiusbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports scpx-20240429.xsd scpx-20240429_def.xml scpx-20240429_lab.xml scpx-20240429_pre.xml scpx_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "scpx_8k.htm": { "nsprefix": "SCPX", "nsuri": "http://scorpiusbiologics.com/20240429", "dts": { "schema": { "local": [ "scpx-20240429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "scpx-20240429_def.xml" ] }, "labelLink": { "local": [ "scpx-20240429_lab.xml" ] }, "presentationLink": { "local": [ "scpx-20240429_pre.xml" ] }, "inline": { "local": [ "scpx_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://scorpiusbiologics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "scpx_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "scpx_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "SCPX_CommonStockPurchaseRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://scorpiusbiologics.com/20240429", "localname": "CommonStockPurchaseRightsMember", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Rights [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://scorpiusbiologics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001079973-24-000604-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-24-000604-xbrl.zip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end XML 19 scpx_8k_htm.xml IDEA: XBRL DOCUMENT 0001476963 2024-04-29 2024-04-29 0001476963 us-gaap:CommonStockMember 2024-04-29 2024-04-29 0001476963 SCPX:CommonStockPurchaseRightsMember 2024-04-29 2024-04-29 iso4217:USD shares iso4217:USD shares false 0001476963 8-K 2024-04-29 Scorpius Holdings, Inc. DE 001-35994 26-2844103 627 Davis Drive Suite 400 Morrisville NC 27560 (919) 240-7133 false false false false Common Stock, $0.0002 par value per share SCPX NYSEAMER Common Stock Purchase Rights None NYSEAMER false